| Recruiting | 1 | 20 | US | Tocilizumab, Actemra, Normal saline, 0.9% NS | Brian Miller, Brain & Behavior Research Foundation | Schizophrenia, Psychotic Disorders | 12/23 | 12/23 | | |
NCT06447376: Study of Cytokine Release Syndrome Prophylaxis and Treatment with Siltuximab Prior to Epcoritamab |
|
|
| Not yet recruiting | 1 | 20 | US | Siltuximab, Epcoritamab | Paolo Caimi, MD, Genmab, AbbVie, Recordati Rare Diseases | Non-Hodgkin Lymphoma, Cytokine Release Syndrome | 09/28 | 09/28 | | |
NCT05665725: Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 1 | 11 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, CNTO-328, Sylvant | Timothy Voorhees | Non-Hodgkin Lymphoma | 12/24 | 12/25 | | |
SILTUXILAM, NCT05697510: Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: |
|
|
| Recruiting | 1 | 12 | Europe | Siltuximab | Nantes University Hospital | Acute Myeloid Leukemia (AML) | 06/25 | 06/25 | | |
NCT05316116: Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) |
|
|
| Recruiting | 1 | 20 | US | Siltuximab, Interleukin-6 | H. Lee Moffitt Cancer Center and Research Institute, EUSA Pharma, Inc. | Large Granular Lymphocyte Leukemia | 01/25 | 01/25 | | |
